AGY vs. INDV, AMYT, APH, BXP, ANCR, VLG, DNL, EAH, STX, and PXS
Should you be buying Allergy Therapeutics stock or one of its competitors? The main competitors of Allergy Therapeutics include Indivior (INDV), Amryt Pharma (AMYT), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), and Provexis (PXS). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Allergy Therapeutics vs.
Indivior (LON:INDV) and Allergy Therapeutics (LON:AGY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
Allergy Therapeutics has lower revenue, but higher earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.
86.0% of Indivior shares are owned by institutional investors. 3.4% of Indivior shares are owned by insiders. Comparatively, 93.0% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Indivior has a net margin of -12.29% compared to Allergy Therapeutics' net margin of -94.29%. Indivior's return on equity of 12.20% beat Allergy Therapeutics' return on equity.
In the previous week, Allergy Therapeutics had 1 more articles in the media than Indivior. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Indivior. Allergy Therapeutics' average media sentiment score of 0.30 beat Indivior's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the news media.
Indivior received 198 more outperform votes than Allergy Therapeutics when rated by MarketBeat users. Likewise, 80.43% of users gave Indivior an outperform vote while only 77.97% of users gave Allergy Therapeutics an outperform vote.
Indivior has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500. Comparatively, Allergy Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Indivior presently has a consensus target price of GBX 1,650, suggesting a potential upside of 65.60%. Given Indivior's stronger consensus rating and higher probable upside, equities analysts clearly believe Indivior is more favorable than Allergy Therapeutics.
Summary
Indivior beats Allergy Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Allergy Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allergy Therapeutics Competitors List
Related Companies and Tools
This page (LON:AGY) was last updated on 1/21/2025 by MarketBeat.com Staff
Free AGY Stock Alerts